CGH: Data analysis of 37 clinical trials shows that there is no association between the use of DAA to treat HCV infection and the increased risk of VZV reactivation

Background and purpose: Recent cases and retrospective studies have aroused people's attention, that is, patients with hepatitis C virus (HCV) infection who received direct antiviral therapy (DAA) developed varicella-zoster virus infection (VZV reactivation) The risk increases
.

We analyzed the data of participants in 37 DAA drug clinical trials to study the relationship between DAA treatment and VZV reactivation

Hepatitis C virus (HCV) infected patients receiving direct antiviral therapy (DAA) are at increased risk of varicella-zoster virus infection (VZV reactivation)

Results: In DAA treatment, there were 9.
9 cases of VZV reactivation every 1000 person-years (95% CI, 6.
8-14.
0/1000 person-years)
.

In the placebo group, there were 13.

The table shows the vzv reactivation rate of 9 test subsets of the placebo control group; with the exception of Test 4 (including 240 trial participants who received 24 weeks of DAA treatment), this subset of trials used 12 weeks of treatment
.

DAA: direct antiviral drugs; VZV: varicella-zoster virus

The table shows the vzv reactivation rate of 9 test subsets of the placebo control group; with the exception of Test 4 (including 240 trial participants who received 24 weeks of DAA treatment), this subset of trials used 12 weeks of treatment

We found no evidence of an association between the use of DAA to treat HCV infection and the increased risk of VZV reactivation

Rohde MD, Tracy L, Komatsu TE, El-Kamary SS, Carter W, No Association Between DAA Treatment for HCV Infection and Herpes Zoster Infection in Analysis of Data From 37 Clinical Trials.

No Association Between DAA Treatment for HCV Infection and Herpes Zoster Infection in Analysis of Data From 37 Clinical Trials.

Leave a message here